• Skip to main content

DistilINFO LifeSciences

Weekly round up from Life Sciences Industry.

  • Publications
    • Home
    • DistilINFO HealthPlan
    • DistilINFO HospitalIT
    • DistilINFO IT
    • DistilINFO Retail
    • DistilINFO POPHealth
    • DistilINFO Ageing
    • DistilINFO Life Sciences
    • DistilINFO GovHealth
    • DistilINFO EHS
    • DistilINFO HealthIndia
    • Subscribe
    • Submit Article
    • Advertise
    • Newsletters

Eisai Launches First Amazon Alexa Skill to Bring Solace & Support to Children with Epilepsy

Share:

November 18, 2019

– Eisai Inc. launches Ella the Jellyfish, the first Amazon Alexa skill designed for those affected by Lennox-Gastaut Syndrome (LGS), a rare and severe form of childhood-onset epilepsy.

– LGS can be characterized by frequent and unpredictable seizures, limited speech and mobility, cognitive impairment, and developmental delays.

– Available free of charge, , this unbranded Alexa skill provides comfort to children, families and caregivers through song, storytelling, meditation, and interactive games.

Eisai Inc., the U.S. subsidiary of Eisai Co., Ltd., today announced the launch of Ella the Jellyfish, the first Amazon Alexa skill designed for those affected by Lennox-Gastaut Syndrome (LGS). Available free of charge, the Alexa skill was created with input from children living with LGS, a rare and severe form of childhood-onset epilepsy, their families and caregivers.

Impact of LSG on Children

Want to publish your own articles on DistilINFO Publications?

Send us an email, we will get in touch with you.

When a child has a debilitating disease, everyday life for them, their families and caregivers can be challenging. LGS can be characterized by frequent and unpredictable seizures, limited speech and mobility, cognitive impairment, and developmental delays. Approximately 70 percent of patients with LGS will show cognitive impairment at diagnosis and more than 50 percent suffer behavioral issues including hyperactivity, sleep disturbances, aggression, and autistic symptoms.

As a result, some children with LGS feel isolated, even from their own family members. Given the need to provide 24-hour-a-day, seven-day-a-week support, families, and caregivers also often feel isolated, exhausted and overwhelmed.

A growing and influential trend transforming healthcare and pharma is the promise and power of voice-enabled technologies such as Amazon Alexa – it often doesn’t provide a way for those in need to receive solace and support – until now. Designed in collaboration with the LGS community, this unbranded Alexa skill provides comfort to children, families and caregivers through song, storytelling, meditation, and interactive games. Available free of charge, it can be downloaded and easily activated on Alexa-enabled devices, including voice assistants, mobile phones and tablets.

Ella the Jellyfish: How It Works

Featuring capabilities such as interactive play, listening, and creative activities, Ella the Jellyfish was designed for easy and seamless daily use on Alexa-enabled devices, including voice assistants, mobile phones and tablets. By simply saying, “Alexa, open Ella the Jellyfish,” families, caregivers and children can instantly and easily interact with Ella and her underwater friends by listening to Ella tell a story, singing a song, listening to a relaxing meditation or playing such games as “Ella Says, Freeze Dance” and “Color Hunt.”

Parents and guardians can enable Ella the Jellyfish skill by searching for Ella the Jellyfish in the Alexa Skills Store online and through the Alexa app. Once enabled, caregivers and patients can start by telling their Alexa-enabled device to open Ella the Jellyfish. Caregivers and patients can also learn how to operate the skill by watching videos of caregivers and children using Ella the Jellyfish. Those videos can be found at ellathejellyfish.com.

“Ella the Jellyfish was born out of the countless, heartfelt experiences Eisai employees have had with the LGS community,” said Alexander Scott, Chief Strategy Officer, Neurology Business Group, Eisai Inc. “Staying true to our human health care mission to advance epilepsy care and help address the specific needs of patients and their families is what inspired us to develop Ella. Our goal is to relentlessly break through ordinary approaches so that we may provide innovative solutions that go beyond just the medicine.”

Impact of Leveraging Voice-Enabled Technology to Address LSG

“When I treat children with LGS, I am always looking for ways to better help support caregivers and families navigate the daily challenges of taking care of someone with this disease,” said Michael Chez, MD, Pediatric Epileptologist, Sutter Medical Group, Sacramento, CA. “Ella is a wonderful example of how technology can provide a new level of support and compassion.”

Source: Hit Consultant

Coffee with DistilINFO's Morning Updates...

Sign up for DistilINFO e-Newsletters.

Just a little bit more about you...
PROCEED
Choose Lists
BACK

Related Stories

  • Global High Potency Active Pharmaceutical Ingredient (HPAPI) Market Report 2022: A $34+ Billion Market in 2026 – Long-Term Forecast to 2031Global High Potency Active Pharmaceutical Ingredient (HPAPI) Market Report 2022: A $34+ Billion Market in 2026 – Long-Term Forecast to 2031
  • New York threatens to block $69B CVS-Aetna mergerNew York threatens to block $69B CVS-Aetna merger
  • Dariohealth Partners with Mediorbis to Bring Telemedicine to Its Mobile Disease Management PlatformDariohealth Partners with Mediorbis to Bring Telemedicine to Its Mobile Disease Management Platform
  • Sonde Health Acquires NeuroLex Lab’s Voice-Based Survey PlatformSonde Health Acquires NeuroLex Lab’s Voice-Based Survey Platform
  • Active Pharmaceutical Ingredient Market to Hit USD 261.28 Billion and Exhibit 6.1% CAGR by 2026Active Pharmaceutical Ingredient Market to Hit USD 261.28 Billion and Exhibit 6.1% CAGR by 2026
  • Mae Launches New Digital Tool Geared Toward Expecting Black PeopleMae Launches New Digital Tool Geared Toward Expecting Black People
  • NeoGenomics Reports Acquisition of Genoptix for $125M in Cash & 1M Common SharesNeoGenomics Reports Acquisition of Genoptix for $125M in Cash & 1M Common Shares
  • Pharmaceutical Aseptic Fill & Finish CMO Market Size 2022 | Industry Share, Growth Factors, Key Company, Developing Technologies, Investment Opportunities, Market Drivers, Challenges & Risks Factors Analysis and Forecast Till 2026Pharmaceutical Aseptic Fill & Finish CMO Market Size 2022 | Industry Share, Growth Factors, Key Company, Developing Technologies, Investment Opportunities, Market Drivers, Challenges & Risks Factors Analysis and Forecast Till 2026

Trending This Week

Sorry. No data so far.

About Us

DistilINFO is media company that publishes Industry news, views and Interviews. We distil the information for you – saving time and keeping you up to date on your interest areas.

More About Us

Follow Us


Useful Links

  • Subscribe
  • Contact
  • Advertise
  • Privacy Policy
  • Terms of Service
  • Feedback

All Publications

  • DistilINFO HealthPlan Advisory
  • DistilINFO HospitalIT Advisory
  • DistilINFO IT Advisory
  • DistilINFO Retail Advisory
  • DistilINFO POPHealth Advisory
  • DistilINFO Ageing Advisory
  • DistilINFO Life Sciences Advisory
  • DistilINFO GovHealth Advisory
  • DistilINFO EHS Advisory
  • DistilINFO HealthIndia Advisory

© DistilINFO Publications